India, November 20, 2026: Indira IVF Hospital Limited has announced an international research collaboration with Prof. Sandro C. Esteves of Androfert, Brazil, Bonraybio Co., Ltd., Taiwan, and ADVY Bioscience Private Limited, India, to advance scientific understanding of male infertility. The initiative, unveiled on International Men’s Day 2026, will focus on prospective clinical studies examining the role of double-strand DNA breaks (DSBs) in sperm and their effect on reproductive and clinical outcomes in assisted reproductive technology (ART).
The research aims to identify thresholds at which double-stranded DNA breaks in sperm begin to impact clinical outcomes, including live birth rates. The collaboration was formalised after discussions at the American Society for Reproductive Medicine (ASRM) Annual Meeting 2025 in San Antonio, Texas.
Global experts to co-lead research
Prof. Sandro C. Esteves, Medical Director of Androfert, Brazil, a specialist in male infertility and reproductive medicine, will co-lead the initiative with Dr. Vipin Chandra, who will head the investigation and global collaboration from Indira IVF. The programme brings together expertise in clinical research, reproductive medicine, and advanced diagnostics.
Bonraybio Co., Ltd. will provide specialised diagnostic technologies for assessing sperm genomic integrity, while ADVY Bioscience Private Limited will support the diagnostic research ecosystem. Indira IVF will lead clinical research activities, supplying study materials, methodologies, analytical frameworks, and data for the programme.
Focus on sperm DNA integrity
Male infertility accounts for nearly 40% of infertility cases worldwide. While conventional sperm DNA fragmentation testing is widely used, the specific impact of sperm DNA double-strand breaks remains insufficiently understood. The collaboration aims to strengthen knowledge of sperm genomic integrity and support the development of more precise diagnostic approaches and treatment strategies in ART.
Dr. Kshitiz Murdia, CEO & Whole-Time Director, Indira IVF Hospital Limited, said the partnership is intended to generate evidence that will enhance scientific understanding of male infertility and support evidence-based fertility treatment approaches. Prof. Esteves added that the research will investigate how double-strand DNA breaks influence fertilisation and embryo viability, aiming to identify clinically significant thresholds.
Industry perspectives on collaboration
Brown Hsu, CEO of Bonraybio Co., Ltd., Taiwan, stated that the collaboration will support the generation of clinical evidence to improve understanding of sperm genomic integrity and its impact on reproductive outcomes. Chetan Raj Singh, President of ADVY Biosciences Private Limited, said the initiative aims to bridge translational research and clinical application in male reproductive health by validating diagnostic approaches for more effective treatment pathways.
The collaboration is expected to contribute to the growing body of evidence on male infertility and support the development of advanced diagnostic techniques in assisted reproductive medicine.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
